Table 62SERM-adverse events vs. placebo

Raloxifene Tamoxifen
Event GroupNumber of TrialsOR (95% CI)Number of TrialsOR (95% CI)
Cardiovascular
Acute Coronary Syndrome31.23(0.92, 1.66)11.19(0.9, 1.58)
Cardiac Death21.25(0.6, 2.78)11.26(0.79, 2.03)
Cerebrovascular Events (serious)31.22(0.89, 1.68)11.16(0.79, 1.72)
Pulmonary Embolism26.26(1.55, 54.8)*13.52(1.37, 10.7)*
Thromboembolic Events72.08(1.47, 3.02)*11.6(0.91, 2.87)
Cancer
Cancer50.9(0.42, 2.04)50.6(0.53, 0.69)*
Breast Cancer20.71(0.1, 7.97)30.49(0.42, 0.57)*
Colon Cancer0NR11.24(0.56, 2.8)
Lung Cancer20.39(0.01, 7.87)11(0.57, 1.76)
Osteosarcoma0NR0NR
GI
GI (mild)80.97(0.78, 1.21)11(0.01, 82)
Upper GI (excluding esophagus)31.1(0.68, 1.81)0NR
Reflux and Esophageal0NR0NR
GI (serious)10.49(0.01, 39.1)0NR
Esophageal (serious)0NR0NR
Upper GI Perforations, Ulcers, or Bleeds (not esophageal)0NR0NR
*

=statistically significant

From: 3, Results

Cover of Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis
Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis [Internet].
Comparative Effectiveness Reviews, No. 12.
MacLean C, Alexander A, Carter J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.